Cargando…

Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis

AIM: To evaluate the cost-consequences of the investment for anti-hepatitis C virus (HCV) treatment by the Italian National Health System (NHS) for patients who will be newly diagnosed through active HCV screening, implemented in Italy from 2020. METHODS: A previously published Markov model was used...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcellusi, Andrea, Simonelli, Claudia, Mennini, Francesco S., Kondili, Loreta A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752541/
https://www.ncbi.nlm.nih.gov/pubmed/34636024
http://dx.doi.org/10.1007/s40258-021-00677-x
_version_ 1784631895383867392
author Marcellusi, Andrea
Simonelli, Claudia
Mennini, Francesco S.
Kondili, Loreta A.
author_facet Marcellusi, Andrea
Simonelli, Claudia
Mennini, Francesco S.
Kondili, Loreta A.
author_sort Marcellusi, Andrea
collection PubMed
description AIM: To evaluate the cost-consequences of the investment for anti-hepatitis C virus (HCV) treatment by the Italian National Health System (NHS) for patients who will be newly diagnosed through active HCV screening, implemented in Italy from 2020. METHODS: A previously published Markov model was used to estimate the disease complications avoided and the associated savings over 20 years to treat a standardised population of 10,000 HCV-infected patients diagnosed as a result of screening. Disease progression probabilities and fibrosis stage distribution were based on previously reported data in the literature. Real-life treatment effectiveness and medical expenses for disease management were estimated starting from a representative cohort of HCV-treated patients in Italy (Italian Platform for the Study of Viral Hepatitis Therapies). The breakeven point in time (BPT) was defined as the years required for the initial investment in treatment to be recovered in terms of cumulative costs saved. RESULTS: Over a 20-year time horizon, the treatment of 10,000 standardized patients diagnosed through active HCV screening results in 7769 avoided events of progression, which are associated with €838.73 million net savings accrued by the Italian NHS. The initial investment in treatment is recouped in 4.3 years in the form of savings from disease complications avoided. CONCLUSION: Investment in treatment of newly diagnosed patients will bring a significant reduction in disease complications, which is associated with great economic benefits. This type of action can reduce the infection rate as well as the clinical and economic disease burden of HCV in Italy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40258-021-00677-x.
format Online
Article
Text
id pubmed-8752541
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-87525412022-01-20 Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis Marcellusi, Andrea Simonelli, Claudia Mennini, Francesco S. Kondili, Loreta A. Appl Health Econ Health Policy Original Research Article AIM: To evaluate the cost-consequences of the investment for anti-hepatitis C virus (HCV) treatment by the Italian National Health System (NHS) for patients who will be newly diagnosed through active HCV screening, implemented in Italy from 2020. METHODS: A previously published Markov model was used to estimate the disease complications avoided and the associated savings over 20 years to treat a standardised population of 10,000 HCV-infected patients diagnosed as a result of screening. Disease progression probabilities and fibrosis stage distribution were based on previously reported data in the literature. Real-life treatment effectiveness and medical expenses for disease management were estimated starting from a representative cohort of HCV-treated patients in Italy (Italian Platform for the Study of Viral Hepatitis Therapies). The breakeven point in time (BPT) was defined as the years required for the initial investment in treatment to be recovered in terms of cumulative costs saved. RESULTS: Over a 20-year time horizon, the treatment of 10,000 standardized patients diagnosed through active HCV screening results in 7769 avoided events of progression, which are associated with €838.73 million net savings accrued by the Italian NHS. The initial investment in treatment is recouped in 4.3 years in the form of savings from disease complications avoided. CONCLUSION: Investment in treatment of newly diagnosed patients will bring a significant reduction in disease complications, which is associated with great economic benefits. This type of action can reduce the infection rate as well as the clinical and economic disease burden of HCV in Italy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40258-021-00677-x. Springer International Publishing 2021-10-12 2022 /pmc/articles/PMC8752541/ /pubmed/34636024 http://dx.doi.org/10.1007/s40258-021-00677-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Marcellusi, Andrea
Simonelli, Claudia
Mennini, Francesco S.
Kondili, Loreta A.
Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis
title Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis
title_full Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis
title_fullStr Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis
title_full_unstemmed Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis
title_short Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis
title_sort economic consequences of anti-hcv treatment of patients diagnosed through screening in italy: a prospective modelling analysis
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752541/
https://www.ncbi.nlm.nih.gov/pubmed/34636024
http://dx.doi.org/10.1007/s40258-021-00677-x
work_keys_str_mv AT marcellusiandrea economicconsequencesofantihcvtreatmentofpatientsdiagnosedthroughscreeninginitalyaprospectivemodellinganalysis
AT simonelliclaudia economicconsequencesofantihcvtreatmentofpatientsdiagnosedthroughscreeninginitalyaprospectivemodellinganalysis
AT menninifrancescos economicconsequencesofantihcvtreatmentofpatientsdiagnosedthroughscreeninginitalyaprospectivemodellinganalysis
AT kondililoretaa economicconsequencesofantihcvtreatmentofpatientsdiagnosedthroughscreeninginitalyaprospectivemodellinganalysis
AT economicconsequencesofantihcvtreatmentofpatientsdiagnosedthroughscreeninginitalyaprospectivemodellinganalysis